Literature DB >> 15958557

Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53.

Anja Krones-Herzig1, Shalu Mittal, Kelly Yule, Hongyan Liang, Chris English, Rafael Urcis, Tarun Soni, Eileen D Adamson, Dan Mercola.   

Abstract

The early growth response 1 (Egr1) gene is a transcription factor that acts as both a tumor suppressor and a tumor promoter. Egr1-null mouse embryo fibroblasts bypass replicative senescence and exhibit a loss of DNA damage response and an apparent immortal growth, suggesting loss of p53 functions. Stringent expression analysis revealed 266 transcripts with >2-fold differential expression in Egr1-null mouse embryo fibroblasts, including 143 known genes. Of the 143 genes, program-assisted searching revealed 66 informative genes linked to Egr1. All 66 genes could be placed on a single regulatory network consisting of three branch points of known Egr1 target genes: TGFbeta1, IL6, and IGFI. Moreover, 19 additional genes that are known targets of p53 were identified, indicating that p53 is a fourth branch point. Electrophoretic mobility shift assay as well as chromatin immunoprecipitation confirmed that p53 is a direct target of Egr1. Because deficient p53 expression causes tumors in mice, we tested the role of Egr1 in a two-step skin carcinogenesis study (144 mice) that revealed a uniformly accelerated development of skin tumors in Egr1-null mice (P < 0.005). These studies reveal a new role for Egr1 as an in vivo tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958557     DOI: 10.1158/0008-5472.CAN-04-3742

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

Review 1.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.

Authors:  Swati Bhattacharyya; Minghua Wu; Feng Fang; Warren Tourtellotte; Carol Feghali-Bostwick; John Varga
Journal:  Matrix Biol       Date:  2011-04-13       Impact factor: 11.583

2.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

3.  Transcriptional Regulation of EGR1 by EGF and the ERK Signaling Pathway in Prostate Cancer Cells.

Authors:  Jennifer Gregg; Gail Fraizer
Journal:  Genes Cancer       Date:  2011-09

4.  Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.

Authors:  David N Boone; Ying Qi; Zhaoliang Li; Stephen R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

5.  Angiotensin II-regulated transcription regulatory genes in adrenal steroidogenesis.

Authors:  Damian G Romero; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Physiol Genomics       Date:  2010-09-28       Impact factor: 3.107

6.  Role of promoter DNA sequence variations on the binding of EGR1 transcription factor.

Authors:  David C Mikles; Brett J Schuchardt; Vikas Bhat; Caleb B McDonald; Amjad Farooq
Journal:  Arch Biochem Biophys       Date:  2014-03-18       Impact factor: 4.013

7.  Hepatic gene expression profiling of 5'-AMP-induced hypometabolism in mice.

Authors:  Zhaoyang Zhao; Takao Miki; Anita Van Oort-Jansen; Tomoko Matsumoto; David S Loose; Cheng Chi Lee
Journal:  Physiol Genomics       Date:  2011-01-11       Impact factor: 3.107

8.  Enthalpic factors override the polyelectrolyte effect in the binding of EGR1 transcription factor to DNA.

Authors:  David C Mikles; Vikas Bhat; Brett J Schuchardt; Caleb B McDonald; Amjad Farooq
Journal:  J Mol Recognit       Date:  2014-02       Impact factor: 2.137

9.  PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Authors:  Jianxiu Yu; Sharon S Zhang; Kan Saito; Scott Williams; Yutaka Arimura; Yuliang Ma; Yuehai Ke; Veronique Baron; Dan Mercola; Gen-Sheng Feng; Eileen Adamson; Tomas Mustelin
Journal:  EMBO J       Date:  2008-12-04       Impact factor: 11.598

10.  Large-scale analysis of network bistability for human cancers.

Authors:  Tetsuya Shiraishi; Shinako Matsuyama; Hiroaki Kitano
Journal:  PLoS Comput Biol       Date:  2010-07-08       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.